Research from Atrium Research, Atrium Research Corporation

Atrium Research

Atrium Research provides institutional quality issuer paid research on public equities in North America. Our investment philosophy takes a 3-5 year view on equities currently being overlooked by the market. Our research process emphasizes understanding the key performance metrics for each specific company, trustworthy management teams, unit economics, and an in-depth valuation analysis.

Our research product includes in-depth initiation reports, research notes, thematic research pieces, and company fact sheets.

Research from Atrium Research

Atrium Research Corporation

Atrium Research provides institutional quality issuer paid research on public equities in North America. Our investment philosophy takes a 3-5 year view on equities currently being overlooked by the market. Our research process emphasizes understanding the key performance metrics for each specific company, trustworthy management teams, unit economics, and an in-depth valuation analysis. 

Our research product includes in-depth initiation reports, research notes, thematic research pieces, and company fact sheets.

Equity Bottom-Up

<ul>
<li>Cannara continues to defend and grow its position amongst LPs throughout geographies and segments, highlighting management execution.</li>
<li>We see several opportunities for Cannara to further penetrate the market as additional grow rooms activate and new products launch.</li>
<li>LOVE is expected to report its Q4 and FY26 financials in late November, for which we expect 17% revenue growth and 11% Adj. EBITDA growth.</li>
</ul>


Cannara continues to defend and grow its position amongst LPs throughout geographies and segments, highlighting management execution.
We see several opportunities for Cannara to further penetrate the market as additional grow rooms activate and new products launch.
LOVE is expected to report its Q4 and FY26 financials in late November, for which we expect 17% revenue growth and 11% Adj. EBITDA growth.


LOVE: Q4 Preview and Hifyre Data Review; Staying Bullish

Cannara Biotech

LOVE: Q4 Preview and Hifyre Data Review; Staying Bullish